Trevor T. Hansel

TL;DR: A single dose of monoclonal antibody to IL-5 decreased blood eosinophils for up to 16 weeks and sputum eosInophils at 4 weeks, which has considerable therapeutic potential for asthma and allergy, however, the findings question the role of eos inophils in mediating the late asthmatic response and causing airway hyper-responsiveness.

TL;DR: It is shown that IL-12 lowers numbers of blood and sputum eosinophils, but without any significant effects on airway hyper-responsiveness or the late asthmatic reaction, and has important implications for development of new anti-inflammatory treatments.

TL;DR: It is suggested that monitoring airway inflammation may be useful in optimizing treatment in children with asthma.

TL;DR: In conclusion, whereas increased IL-4 levels were found only in diseases characterized by increased IgE production, IL-5 was elevated in all patients with increased numbers of eosinophils and may represent the ongoing inflammatory responses.

TL;DR: Infliximab was associated with a decrease in mean diurnal variation of PEF at week 8 (p = 0.02; 95% confidence interval [CI], −8.1 to −0.72).